ClinicalTrials.gg
CompletedNCT05292131Updated Apr 10, 2025Results posted

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

A Phase 1 interventional study of bimekizumab in Healthy Study Participants, sponsored by UCB Biopharma SRL. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the study is to compare the pharmacokinetics (PK), safety and tolerability of a single subcutaneous (sc) dose of bimekizumab (BKZ) when administered using bimekizumab-autoinjector (AI)-2mL presentation versus bimekizumab-AI-2x1mL presentation in healthy study participants.

02

Conditions studied

  • Healthy Study Participants

Keywords

  • UCB4940
  • BKZ
  • bimekizumab
  • Bioequivalence
  • Auto-injector
  • Healthy study participants
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be ≥18 years and ≤65 years of age inclusive, at the time of signing the
  • Study participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, 12-lead (ECG), and laboratory tests, during the Screening Period and on admission
  • Study participant has a body temperature between 35.0°C and 37.5°C, inclusive, at Screening and on admission
  • Body weight minimum of 50 kg for male and 45 kg for female study participants and a maximum of 100 kg for all study participants, and (BMI) within the range 18 to 32 kg/m\^2 (inclusive) at the Screening Visit
  • Male or female. guidelines (as per the standard UCB contraceptive guideline) will be applicable.

Exclusion criteria

Exclusion Criteria:

  • Study participant has a known to any components of the bimekizumab (and/or an device) as stated in this protocol
  • Study participant has an active infection or history of infections as follows:
  • Any active infection (except common cold) within 14 days prior to Screening Visit
  • A serious infection, defined as requiring hospitalization or iv anti-infectives within 2 months prior to the Screening Visit
  • A history of opportunistic, recurrent, or chronic infections that, in the opinion of the Investigator, might cause this study to be detrimental to the study participant. Opportunistic infections are infections caused by uncommon pathogens (eg, pneumocystis jirovecii, cryptococcosis) or unusually severe infections caused by common pathogens (eg, cytomegalovirus, herpes zoster)
  • Study participant has a history of a positive TB test or evidence of possible TB or latent TB infection at Screening Visit. Refer to Tuberculosis Detection Procedure Guideline for details regarding TB infection status, detection procedures, and the related exclusion criteria
  • Study participants receiving any live (includes attenuated) vaccination within the 8 weeks prior to the Screening Visit (eg, inactivated influenza and pneumococcal vaccines are allowed, but nasal influenza vaccination is not permitted). are not allowed during the study or for 20 weeks after the last dose of the investigational medicinal product (IMP)
  • Study participant has previously participated in this study or a study participant has previously been assigned to bimekuzimab treatment in any other study
  • Exposure to 3 or more new chemical entities within 12 months prior to dosing
  • Current enrollment or past participation within the last 30 days before signing the form (ICF) in any other clinical study involving an investigational study intervention or any other type of medical research
  • Study participant has concurrent acute or chronic viral or C or (HIV) infection. Study participants who have evidence of, or tested positive for hepatitis B or are excluded
  • Study participant has made a blood donation of a blood loss of more than 400 mL of blood or blood products within 90 days prior to admission (Day -1) or plans to donate blood during the study
  • Female study participant who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with who is not using a medically accepted method
  • Study participant has an alcohol consumption of more than 21 units (males) or 14 units (females) of alcohol per week (1 unit of alcohol is equivalent to 12.5 mL ethanol at room temperature)
  • Study participant tests positive for alcohol or drugs (urine test) at Screening or Day -1
  • Vulnerable study participants (eg, participants kept in detention, protected adults under guardianship or trusteeship, and soldiers or participants committed to an institution by governmental or juridical order), employees of the Sponsor or the contract research organization (CRO) with direct involvement in the proposed study or other studies under the direction of the Investigator or the CRO, as well as family members of the employees or the Investigator
  • Study participant has a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in real-time reverse transcriptase polymerase chain reaction (RT-PCR) on the admission sample
  • Study participant has clinical signs and symptoms consistent with COVID-19, eg fever, dry cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test within the previous 14 days prior to Screening or on admission
  • Study participant who had severe course of COVID-19 (ie, hospitalization, extracorporal membrane oxygenation, mechanically ventilated)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Test

    Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-2mL presentation (test).

    Drug: bimekizumab

  • Other
    Reference

    Study participants randomized to this arm will receive bimekizumab (BKZ) administered subcutaneously with bimekizumab-AI-1x2mL presentation (reference).

    Drug: bimekizumab

Interventions

  • Study participants will receive a single dose of bimekizumab (BKZ) administered subcutaneously in the Treatment Period.

    Also known as: BKZ; UCB4940

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)

    AUC is the area under the plasma concentration-time curve from time 0 (Day 1 predose) to infinity.

    Time frame: Baseline (Day 1 predose) at predefined time points (up to Day 140)

  2. Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)

    AUC0-t is the area under the plasma concentration-time curve from time zero (Day 1 predose) to the last quantifiable concentration.

    Time frame: From Baseline (Day 1 predose) at predefined time points to the last quantifiable concentration (Day 140)

  3. Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)

    Cmax is a maximum observed plasma concentration.

    Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)

Secondary outcomes

  1. Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up

    An AE is any untoward medical occurrence in a patient or clinical study participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as AEs not present prior to the administration of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to study treatment.

    Time frame: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)

  2. Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up

    A SAE is defined as any untoward medical occurrence that at any dose: a. Results in death, b. Is life-threatening, c. Requires inpatient hospitalization or prolongation of existing hospitalization, d. Results in persistent disability/incapacity, e. Is a congenital anomaly/ birth defect, f. Is an important medical event which based on appropriate medical judgment, jeopardized the study participant and required medical or surgical intervention to prevent any of the above.

    Time frame: From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)

  3. Apparent Terminal Half-life (t1/2)

    Apparent terminal half-life as determined via linear regression (slope=-lamdbaz) of the natural log (ln) concentration versus time, for data points in the terminal phase of the concentration time curve (ln2/lambdaz).

    Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)

  4. Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)

    tmax is the time to reach maximum plasma concentration.

    Time frame: From Baseline (Day 1 predose) at predefined time points (up to Day 140)

07

Results

Posted Apr 10, 2025

Participant flow

The study started to enroll participants in March 2022 and concluded in January 2023.

Participant flow — Overall Study
MilestoneBimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Started6061
Completed5959
Not completed12
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)

AUC is the area under the plasma concentration-time curve from time 0 (Day 1 predose) to infinity.

Time frame:
Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Geometric least squares mean · days*micrograms/milliliter (days*ug/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)
days*micrograms/milliliter (days*ug/mL)Bimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) for a Single Dose Bimekizumab (BKZ)1223 (1146.1 to 1306.1)1255 (1174.2 to 1341.1)
Statistical analysis
  • Bimekizumab-AI-2mL (Test) vs Bimekizumab-AI-2x1mL (Reference) · Geometric mean ratio (percentage [%]): 97.50 · 90% CI 90.20 to 105.40
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)

AUC0-t is the area under the plasma concentration-time curve from time zero (Day 1 predose) to the last quantifiable concentration.

Time frame:
From Baseline (Day 1 predose) at predefined time points to the last quantifiable concentration (Day 140)
Reported as:
Geometric least squares mean · day*ug/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)
day*ug/mLBimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for a Single Dose Bimekizumab (BKZ)1186 (1114.7 to 1262.9)1223 (1147.3 to 1302.6)
Statistical analysis
  • Bimekizumab-AI-2mL (Test) vs Bimekizumab-AI-2x1mL (Reference) · Geometric mean ratio (%): 97.05 · 90% CI 90.10 to 104.55
PrimaryMaximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)

Cmax is a maximum observed plasma concentration.

Time frame:
From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Geometric least squares mean · micrograms/milliliter (ug/mL)
Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)
micrograms/milliliter (ug/mL)Bimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Maximum Plasma Concentration (Cmax) for a Single Dose Bimekizumab (BKZ)35.17 (32.8 to 37.7)36.55 (34.1 to 39.2)
Statistical analysis
  • Bimekizumab-AI-2mL (Test) vs Bimekizumab-AI-2x1mL (Reference) · Geometric mean ratio (%): 96.21 · 90% CI 88.60 to 104.47
SecondaryPercentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up

An AE is any untoward medical occurrence in a patient or clinical study participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are defined as AEs not present prior to the administration of IMP or any unresolved event already present before administration of IMP that worsens in intensity following exposure to study treatment.

Time frame:
From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up
percentage of participantsBimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) From Baseline to End of Safety Follow-Up43.349.2
SecondaryPercentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up

A SAE is defined as any untoward medical occurrence that at any dose: a. Results in death, b. Is life-threatening, c. Requires inpatient hospitalization or prolongation of existing hospitalization, d. Results in persistent disability/incapacity, e. Is a congenital anomaly/ birth defect, f. Is an important medical event which based on appropriate medical judgment, jeopardized the study participant and required medical or surgical intervention to prevent any of the above.

Time frame:
From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up
percentage of participantsBimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Percentage of Participants With at Least One Treatment-emergent Serious Adverse Event (SAE) From Baseline to End of Safety Follow-Up00
SecondaryApparent Terminal Half-life (t1/2)

Apparent terminal half-life as determined via linear regression (slope=-lamdbaz) of the natural log (ln) concentration versus time, for data points in the terminal phase of the concentration time curve (ln2/lambdaz).

Time frame:
From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Geometric least squares mean · days
Apparent Terminal Half-life (t1/2)
daysBimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Apparent Terminal Half-life (t1/2)24.65 (23.2 to 26.2)24.38 (22.9 to 25.9)
Statistical analysis
  • Bimekizumab-AI-2mL (Test) vs Bimekizumab-AI-2x1mL (Reference) · Geometric mean ratio (%): 101.13 · 90% CI 94.18 to 108.59
SecondaryTime of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)

tmax is the time to reach maximum plasma concentration.

Time frame:
From Baseline (Day 1 predose) at predefined time points (up to Day 140)
Reported as:
Median · day
Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)
dayBimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
Time of Occurrence of the Maximum Observed Concentration (Tmax) of a Single Dose Bimekizumab (BKZ)6.962 (2.96 to 12.0)5.979 (2.00 to 21.0)
Statistical analysis
  • Bimekizumab-AI-2mL (Test) vs Bimekizumab-AI-2x1mL (Reference) · Hodges-lehman estimate: 0.4897 · 90% CI -0.0073 to 0.9567

Adverse events

Collected over From Baseline (Day 1) to end of Safety Follow-Up (up to Day 140). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimekizumab-AI-2mL (Test)0/60 (0%)0/60 (0%)11/60 (18.3%)
Bimekizumab-AI-2x1mL (Reference)0/61 (0%)0/61 (0%)16/61 (26.2%)
Most frequent other events
Most frequent other events
EventBimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)
HeadacheNervous system disorders8/608/61
NasopharyngitisInfections and infestations4/607/61
FatigueGeneral disorders1/604/61

Baseline characteristics

Baseline characteristics refer to the SS which consisted of all study participants randomized and received full or partial IMP according to the treatment the participants actually received.

Age, Continuous
Age, Continuous(Years)Bimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)Total
Mean45.6 ± 11.744.8 ± 11.345.2 ± 11.5
Age, Customized
Age, Customized(Participants)Bimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)Total
18 - <65 yrs6059119
65 - <85 yrs022
Sex: Female, Male
Sex: Female, Male(Participants)Bimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)Total
Female242448
Male363773
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)Total
Asian437
Black or African American4610
Native Hawaiian or Other Pacific Islander101
White5050100
Other or Mixed123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bimekizumab-AI-2mL (Test)Bimekizumab-AI-2x1mL (Reference)Total
Hispanic or Latino121224
Not Hispanic or Latino484997
08

Study locations

2 sites
  • UP0119 2
    Glendale, California 91206, United States
  • UP0119 1
    Berlin, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Data from Phase 1 trials in Healthy Volunteers is outside of UCB's data sharing policy and is unavailable for sharing.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Jan 2023, 9 months.

Results were first posted in Apr 2025, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2022
First posted
Mar 23, 2022
StartActual
Mar 17, 2022
Primary completionActual
Jan 9, 2023
CompletionActual
Jan 9, 2023
Results first posted
Apr 10, 2025
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05292131
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
Mar 17, 2022
Primary completion
Jan 9, 2023
Completion
Jan 9, 2023
Results posted
Apr 10, 2025
Last update
Apr 10, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion